Advertisement

Epizyme Inc., a Cambridge firm focused on personalized cancer therapeutics, is due to receive up to $7.5 million in milestone payments from the Leukemia & Lymphoma Society for the development of the company’s DOT1L-targeted histone methyltransferase inhibitor for Mixed Lineage Leukemia (MLL), a blood cancer that can hit both pediatric and adult patients.

The funding from LLS will cover Epizyme’s development of the leukemia treatment through Phase 1 trials.

SOURCE

Advertisement
Advertisement